Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.53 |
| ▸ | AURKA | O14965 | 4/20 | 0.53 |
| ▸ | MET | P08581 | 4/20 | 0.53 |
| ▸ | TEK | Q02763 | 4/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.53 |
| ▸ | RET | P07949 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
| ▸ | FLT1 | P17948 | 2/20 | 0.51 |
| ▸ | FLT4 | P35916 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | STK10 | O94804 | 1/20 | 0.51 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | BCR | P11274 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25028718 | 0.93 | PDGFRB (0.54) | KDRAURKBAURKAMETTEK | |
| SCHEMBL25028721 | 0.91 | KDR (0.51) | KDRAURKBAURKAMETTEK | |
| SCHEMBL25028726 | 0.90 | KDR (0.55) | KDRAURKBAURKAMETTEK | |
| SCHEMBL25028723 | 0.86 | KDR (0.58) | KDRAURKBAURKAMETTEK | |
| SCHEMBL25028717 | 0.85 | PDGFRB (0.54) | KDRAURKBAURKAMETTEK | |
| SCHEMBL25029460 | 0.84 | KDR (0.55) | KDRAURKBAURKAMETTEK | |
| SCHEMBL25028719 | 0.83 | PDGFRB (0.53) | KDRAURKBAURKAMETTEK | |
| SCHEMBL22295341 | 0.83 | PDGFRB (0.58) | KDRAURKBAURKAMETTEK | |
| SCHEMBL25028733 | 0.83 | KDR (0.52) | KDRAURKBAURKAMETTEK | |
| SCHEMBL25028724 | 0.83 | KDR (0.54) | KDRAURKBAURKAMETTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912663-B2 | Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses | SHANGHAI AB PHARMATECH LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| US-11912663-B2 | Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses | SHANGHAI AB PHARMATECH LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| US-20230124784-A1 | MULTI-TARGETED TYROSINE KINASE INHIBITORS AND THEIR PHARMACEUTICAL USES | SHANGHAI AB PHARMATECH LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| WO-2023016540-A1 | UREA MULTI-TARGET TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | 上海爱博医药科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016543-A1 | UREA MULTI-TARGET TYROSINE KINASE INHIBITOR AND MULTIPLE MEDICAL APPLICATIONS THEREOF | 上海爱博医药科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912663-B2 | Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses | ABL1, ERBB2, RET | KDR 429/4885AURKB 278/4885AURKA 335/4885 |
| US-20230124784-A1 | MULTI-TARGETED TYROSINE KINASE INHIBITORS AND THEIR PHARMACEUTICAL USES | ABL1, ERBB2, RET | KDR 429/4885AURKB 278/4885AURKA 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.